ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026

Romosozumab is effective in patients with variants in LRP5, LRP6, or WNT1.

Felix N von Brackel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.